Essex Investment Management Co. LLC Has $357,000 Holdings in LENSAR, Inc. (NASDAQ:LNSR)

Essex Investment Management Co. LLC lifted its position in LENSAR, Inc. (NASDAQ:LNSR) by 18.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 39,890 shares of the company’s stock after acquiring an additional 6,184 shares during the quarter. Essex Investment Management Co. LLC’s holdings in LENSAR were worth $357,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LNSR. Geode Capital Management LLC raised its stake in LENSAR by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock valued at $460,000 after purchasing an additional 3,423 shares during the period. Atria Investments Inc grew its holdings in shares of LENSAR by 28.2% during the fourth quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock valued at $233,000 after buying an additional 5,729 shares in the last quarter. Evernest Financial Advisors LLC acquired a new position in LENSAR during the fourth quarter valued at $174,000. Finally, Bailard Inc. acquired a new position in LENSAR during the fourth quarter valued at $181,000. Institutional investors and hedge funds own 40.15% of the company’s stock.

LENSAR Stock Performance

Shares of LNSR opened at $14.86 on Monday. The company has a market capitalization of $175.18 million, a PE ratio of -10.18 and a beta of 0.62. The company’s 50 day moving average price is $10.15 and its 200 day moving average price is $7.45. LENSAR, Inc. has a 52 week low of $2.67 and a 52 week high of $16.40.

LENSAR (NASDAQ:LNSR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.40). LENSAR had a negative net margin of 34.03% and a negative return on equity of 49.02%. The company had revenue of $16.73 million for the quarter, compared to analysts’ expectations of $14.95 million.

Analysts Set New Price Targets

Separately, Lake Street Capital raised their price objective on LENSAR from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, February 28th.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.